ABSTRACT
Follistatin like protein 1 (FSTL1) is a famous growth regulatory protein. FSTL1 has been noticed in many diseases, including heart and lung ischemia, cerebral ischemia, glioma, schizophrenia, and Autism. The role of FSTL1 has been declared in the genetics and development of the central nervous system. Therefore, we designed this study to investigate the function and the role of FSTL1 in Alzheimer's disease. Firstly, we noticed upregulated expression level of FSTL1 among four to six-month-old 5XFAD AD mice. Accordingly, we hypothesized that FSTL1-Knockdown improved AD model mice's cognitive function and recover from Alzheimer's disease. Thus, AD model mice were made by single intracerebroventricular injections of Aß1-42 peptides in FSTL1+/- and CON mice. Next, our results concluded that FSTL1-knockdown effectively improved cognitive functions. FSTL1-knockdown enhanced the pattern of neural oscillations, and synaptic plasticity in Aß1-42 treated FSTL1-Knockdown mice compared to Aß1-42 induced AD model mice. Next, FSTL1-Knockdown inhibited the activation of microglia and binding of TLR-4 with microglia. Further, inactivated microglia stopped the formation of MyD88. Thus, our data revealed that FSTL1-Knockdown is slowing down the caspase/BAX/Bcl-2/TLR-4 regulating apoptosis pathway, and the expression of inflammatory cytokines in the hippocampus of Aß1-42 inserted FSTL1-Knockdown mice. Overall, all these data illuminate the clinical significance role of down-regulated FSTL1. FSTL1-Knockdown reduced the amyloid-beta by affecting microglia, neural-inflammation and apoptosis in AD-like model mice. Finally, down regulation of FSTL1 improved synaptic plasticity, neural oscillations, and cognitive behaviours in the Aß1-42 induced AD model mice.
Subject(s)
Alzheimer Disease , Follistatin-Related Proteins , Animals , Mice , Alzheimer Disease/chemically induced , Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Follistatin-Related Proteins/genetics , Toll-Like Receptor 4/metabolism , Amyloid beta-Peptides/metabolism , Peptide Fragments/metabolism , Apoptosis , Inflammation/chemically induced , Inflammation/metabolism , Disease Models, AnimalABSTRACT
The gene of Disrupted-in-schizophrenia 1 (Disc1) is closely related to mental diseases with cognitive deficits, but there are few studies on the changes in neural oscillations and recognition memory. Neural oscillations plays a key role in the nervous system in a dynamic form, which is closely related to advanced cognitive activities such as information processing and memory consolidation. Hence, we aimed to investigate if Disc1 knockdown disrupted the normal pattern of neural activities in the mouse hippocampus network, and determined if quantitative neural oscillation approach could be a potential diagnostic tool for mental disorders. In the study, we reported that Disc1 gene, downregulated by short-hairpin RNA (shRNA), not only induced anxiety-like behavior and sociability impairment but also damaged both synaptic plasticity and recognition memory in mice. Moreover, Disc1 knockdown mice exhibited evidently abnormal power spectral distributions, reduced phase synchronizations, and decreased phase-amplitude coupling strength compared to that of normal animals. In addition, transcriptome analyses showed that there were clearly transcriptional changes in Disc1 knockdown mice. Altogether, our findings suggest that the abnormal pattern of neural activities in the hippocampus network disrupts information processing and finally leads to the impairments of synaptic plasticity and recognition in Disc1 knockdown mice, which are possibly associated with the obstruction of neurotransmitter transmission. Importantly, the data imply that the analysis of neural oscillation pattern provides a potential diagnosis approach for mental disorders.
Subject(s)
Down-Regulation , Hippocampus/metabolism , Nerve Tissue Proteins/genetics , Neuronal Plasticity/genetics , Neurons/physiology , Recognition, Psychology/physiology , Animals , Behavior, Animal/physiology , Mice , Nerve Tissue Proteins/metabolismABSTRACT
The imbalance of amyloid-ß (Aß) production and clearance causes aggregation of Aß1-42 monomers to form fibrils and amyloid plaques, which is an indispensable process in the pathogenesis of Alzheimer's disease (AD), and eventually leads to pathological changes and cognitive impairment. Consequently, Aß1-42 is the most important target for the treatment of AD. However, developing a single treatment method that can recognize Aß1-42 , inhibit Aß1-42 fibrillation, eliminate amyloid plaques, improve cognitive impairments, and alleviate AD-like pathology is challenging. Here, a coassembly composed of cyclodextrin (CD) and calixarene (CA) is designed, and it is used as an anti-Aß therapy agent. The CD-CA coassembly is based on the previously reported heteromultivalent recognition strategy and is able to successfully eliminate amyloid plaques and degrade Aß1-42 monomers in 5xFAD mice. More importantly, the coassembly improves recognition and spatial cognition deficits, and synaptic plasticity impairment in the 5xFAD mice. In addition, the coassembly ameliorates AD-like pathology including prevention of neuronal apoptosis and oxidant stress, and alteration of M1/M2 microglial polarization states. This supramolecular approach makes full use of both molecular recognition and self-assembly of macrocyclic amphiphiles, and is a promising novel strategy for AD treatment.
Subject(s)
Alzheimer Disease/drug therapy , Amyloid beta-Peptides/metabolism , Macrocyclic Compounds/chemistry , Macrocyclic Compounds/pharmacology , Animals , Humans , Macrocyclic Compounds/therapeutic use , MiceABSTRACT
Neuroinflammation is the important pathological feature of Alzheimer's disease (AD). Legumain, a lysosomal cysteine protease, plays an important role in neuroinflammation during ischemic stroke and depressive disorder. Legumain is involved in AD process through cleaving APP; however, it is unclear if legumain can possibly modulate neuroinflammation without cleaving APP in AD. Thus, we established a mouse model of AD by single intracerebroventricular injections of Aß1-42 in legumain knockout (KO) mice. The behavioral tests showed that legumain-KO effectively ameliorated cognitive impairment induced by Aß1-42. Moreover, legumain deprivation significantly improves the synaptic plasticity damages in Aß1-42-treated mice. Moreover, legumain-KO considerably inhibited the activation of microglia and reduced the expression of inflammatory cytokines in the hippocampus of Aß1-42-treated mice. Interestingly, we found that legumain-KO inhibited TLR4/MyD88/NF-κB pathway, which was activated by Aß1-42 in the hippocampus. In conclusion, our results suggested that legumain-KO reduced the level of neuroinflammation that was associated with inhibiting TLR4/MyD88/NF-κB pathways, thereby improving the hippocampal synaptic plasticity and reducing the cognitive impairments in Aß1-42-treated mice. Legumain knockout blocked microglia activation by inhibiting TLR4/MyD88/NF-κB signaling pathways, and further reduced inflammatory cytokine expression. As a result, legumain knockout alleviated synaptic damage and cognitive impairment induced by Aß1--42.
Subject(s)
Alzheimer Disease/complications , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/toxicity , Brain/pathology , Cognitive Dysfunction/complications , Cysteine Endopeptidases/deficiency , Inflammation/pathology , Neuronal Plasticity , Peptide Fragments/toxicity , Animals , Brain/physiopathology , Cognitive Dysfunction/physiopathology , Cysteine Endopeptidases/metabolism , Hippocampus/metabolism , Hippocampus/pathology , Hippocampus/physiopathology , Inflammation/complications , Memory Disorders/complications , Memory Disorders/physiopathology , Mice, Knockout , Myeloid Differentiation Factor 88/metabolism , NF-kappa B/metabolism , Signal Transduction/drug effects , Spatial Learning , Toll-Like Receptor 4/metabolismABSTRACT
Prenatal stress (PS) induces cognitive deficits, abnormal behavior patterns and physical impairments in offspring, which disturbs the developmental process. GABA systems play a key role in the brain development. The developmental trajectories are less understood although PS increases the expression of GABAAR in young offspring. In the present study, we aimed to examine if the long-lasting effects on memory function and hippocampal synaptic plasticity induced by PS were associated with the GABA function throughout developmental process. Thus, a PS rat model was established by using restraint stress three 45-min periods per day from gestational day 15 until delivery. PS-exposed offspring exhibited the memory function deficits, LTP and depotentiation inhibitions in young and puberty offspring, but the disorder resolved at adult offspring. Meanwhile, the hippocampal spine density was decreased by PS in offspring. Additionally, we found that the balance of excitatory and inhibitory receptors was significantly disturbed after PS. The immunostaining of parvalbumin level was increased in the PS group. Overall, these all results suggest that the PS induces negative effects in memory and hippocampal synaptic plasticity in the early developmental stage, which could be an underlying mechanism of the disturbed GABA function.
Subject(s)
Prenatal Exposure Delayed Effects , gamma-Aminobutyric Acid , Animals , Female , Hippocampus , Male , Memory , Neuronal Plasticity , Pregnancy , RatsABSTRACT
The concise total synthesis of aplykurodinone-1 with an unusual cis-fused hydrindane moiety has been accomplished without the need for any protecting group chemistry using a unique SmI2 mediated reductive cascade cyclization reaction and a direct cuprate mediated 1,4-addition. This work represents the first example of the use of a SmI2-mediated intramolecular cascade cyclization reaction between "halide, alkene and aldehyde" groups.